What is Character?
Character Biosciences, formerly known as Clover Therapeutics, was founded in 2020 and is headquartered in Jersey City, New Jersey. The company is dedicated to advancing precision medicine, with a primary focus on developing targeted therapies for progressive polygenic diseases. Its initial efforts are concentrated on ophthalmology, specifically addressing age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG). By leveraging a sophisticated integration of genomics, extensive clinical data, and advanced AI-driven modeling, Character Biosciences aims to enhance the success rates of drug development by identifying the critical genetic and molecular drivers of disease progression.
How much funding has Character raised?
Character has raised a total of $136.9M across 3 funding rounds:
Other Financing Round
$18M
Series B
$110M
Private Equity
$8.9M
Other Financing Round (2022): $18M with participation from Innovation Endeavors and Section 32
Series B (2025): $110M led by S32, Bausch & Lomb, Catalio Capital Management, Luma Group, KdT Ventures, aMoon, and Innovation Endeavors
Private Equity (2025): $8.9M, investors not publicly disclosed
Key Investors in Character
S32
S32 (SISTEMA 32) is an investor focused on integrated kitchens, wardrobes, and furniture, offering innovative design solutions. Their involvement suggests a potential interest in the operational or infrastructure aspects supporting biotech development, or a diversified investment strategy.
Bausch & Lomb
Bausch & Lomb is a global eye health company that develops, manufactures, and markets a wide range of healthcare products, including ophthalmic pharmaceuticals and surgical devices. Their participation strongly indicates strategic alignment with Character Biosciences' focus on ophthalmology, particularly AMD and POAG.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare and biomedical technology companies across various market stages. Their investment in Character Biosciences highlights a focus on cutting-edge therapies and potentially disruptive technologies within the life sciences sector.
What's next for Character?
The substantial enterprise-level funding secured by Character Biosciences signals a pivotal growth phase for the company. This capital injection is expected to accelerate the development and clinical validation of its targeted therapies, particularly in the ophthalmology sector. The company's strategic focus on polygenic diseases, combined with its AI-driven approach, positions it to potentially disrupt current treatment paradigms. Future endeavors will likely involve expanding its research pipeline, forging strategic partnerships, and navigating the complex regulatory pathways to bring novel treatments to patients.
See full Character company page
